MXCT News and Press, MaxCyte Inc. From 05/12/23

2023-05-12 13:39:06 ET MaxCyte, Inc. (MXCT) Q1 2023 Earnings Conference Call May 10, 2023 04:30 PM ET Company Participants Sean Menarguez - Head-Investor Relations Doug Doerfler - President & Chief Executive Officer Douglas Swirsky - Chief Financial Office ...

2023-05-10 16:29:01 ET MaxCyte press release ( NASDAQ: MXCT ): Q1 GAAP EPS of -$0.11. Revenue of $8.6M (-25.7% Y/Y). Total cash, cash equivalents and short-term investments were $224.7 million as of March 31, 2023. Gross profit for the first quarter of 2023 was $...

ROCKVILLE, Md., May 10, 2023 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell therapeutics and to support innovati...

ROCKVILLE, Md., May 04, 2023 (GLOBE NEWSWIRE) -- MaxCyte, Inc. , (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to suppor...

ROCKVILLE, Md., April 12, 2023 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support innovat...

2023-04-12 04:49:05 ET Summary MaxCyte’s flow electroporation technology has made them the industry leader and the best bet for biotech companies that need a partner that specializes in non-viral cell engineering. MaxCyte’s revenue mostly comes from milestone and roy...

2023-03-27 17:06:39 ET MaxCyte ( NASDAQ: MXCT ) on Monday said Douglas Swirsky has been appointed chief financial officer, effective immediately. Swirsky, who has over two decades of experience in the healthcare sector, notably served as CEO of Rexahn...

ROCKVILLE, Md., March 27, 2023 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support i...

2023-03-15 21:41:35 ET The following slide deck was published by MaxCyte, Inc. in conjunction with their 2022 Q4 earnings call. For further details see: MaxCyte, Inc. 2022 Q4 - Results - Earnings Call Presentation

2023-03-15 21:41:02 ET MaxCyte, Inc. (MXCT) Q4 2022 Earnings Conference Call March 15, 2023 16:30 ET Company Participants Sean Menarguez - Investor Relations Doug Doerfler - President and Chief Executive Officer Ron Holtz - Interim Chief Financial Officer C...